Am­gen is join­ing the bio­phar­ma ex­o­dus out of neu­ro­sciences R&D, cut­ting 180 R&D jobs in re­or­ga­ni­za­tion

Three months af­ter Am­gen fold­ed up a late-stage Alzheimer’s study of their failed BACE in­hibitor part­nered with No­var­tis, the phar­ma gi­ant is join­ing the gen­er­al ex­o­dus out of neu­ro­sciences. And they’re cut­ting some 180 po­si­tions as a re­sult of the re­or­ga­ni­za­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER